[Westport Pharmaceuticals LLC] fared better in a National Advertising Division review of ad claims for its Zephrex-D nasal decongestant than it did in a federal agency’s review of an extraction-proof claim for the pseudoephedrine product.
NAD said June 12 that Westport supported claims for Zephrex-D’s rate of relief and efficacy challenged by Acura Pharmaceuticals Inc. , manufacturer of Nexafed, another nonprescription 30 mg PSE...